Peptides, Patents & the Law
Peptides sit at the intersection of biology, medicinal chemistry, patent law, drug regulation, pharmacy law, and commercial enforcement. A molecule can be patent-protected and still lack FDA approval. A patent can expire without making a product automatically lawful to sell. And a vial labeled “research use only” can still attract regulatory scrutiny if the surrounding marketing shows an intended human-drug use.
FDA peptide compounding policy enters White House review
The Office of Information and Regulatory Affairs lists an FDA notice titled Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94), received October 14, 2026, as pending review.
This record documents review, not an effective policy. The public entry does not provide the policy text, identify covered peptides, or give an effective date. It therefore does not establish that any particular peptide may now be compounded or that a product is FDA-approved. We will assess the scope and conditions against published FDA policy rather than infer them from the title.
Primary source: OIRA — pending regulatory review, RIN 0910-ZD94. Status checked October 16, 2026.
Reported European semaglutide patent revocation
Specialist publications JUVE Patent and ip fray report that the European Patent Office's Board of Appeal revoked Novo Nordisk's European patent EP 3 448 416, titled Semaglutide in cardiovascular conditions. ip fray published its report on October 12, 2026.
Verification status: PeptideSciences101 reviewed the available specialist reporting and published patent text, but could not retrieve the official EPO appeal decision or independently confirm its operative order and reasoning. The revocation is therefore presented here as a reported outcome. We do not attribute specific legal grounds to the board.
The published patent concerns a cardiovascular therapeutic use of semaglutide. Our interpretation: a reported outcome concerning one such patent should not be read as clearance of every patent covering semaglutide products. This update does not establish that a generic Ozempic or Wegovy product may launch, or predict its launch date. Patent rights and medicines authorization are separate questions; a European patent report is not a change to U.S. compounding policy.
Reporting: JUVE Patent — reported revocation; ip fray — October 12 report. Patent text: EP 3 448 416 B1. Official record for follow-up: European Patent Register. The register link identifies the record to verify; it is not evidence that we independently reviewed the appeal decision.
Read the UK update, with media-reported figures separated from MHRA announcements and unresolved legal questions.
Read the filing and learn why generic approval, patent clearance, and compounding are separate questions.
Earlier: Seventh Circuit hears Lilly's retatrutide classification appeal
The U.S. Court of Appeals for the Seventh Circuit heard oral argument in Eli Lilly and Company v. Kennedy, No. 26-1301, Lilly's appeal concerning FDA's classification of investigational retatrutide. The panel questioned whether it has appellate jurisdiction while part of the classification dispute remains on remand to FDA. The court directed the parties to submit supplemental memoranda on jurisdiction by October 8, 2026.
No appellate decision has been issued. Questions from judges during oral argument are not holdings, and the jurisdiction issue has not been decided. The district court previously upheld FDA's conclusion that retatrutide does not meet the regulatory definition of a protein, while vacating and remanding FDA's separate conclusion that retatrutide is not analogous to a protein. The district court did not rule that retatrutide is a biological product.
Why it matters: if the Seventh Circuit concludes that it lacks jurisdiction, the appeal could end without the court deciding the protein-definition merits, leaving the analogous-product question with FDA on remand. If the court reaches the merits, its decision could affect the regulatory pathway applicable to retatrutide. None of this changes retatrutide's current status as an investigational, unapproved product.
Primary source: U.S. Court of Appeals for the Seventh Circuit — oral argument record, No. 26-1301, September 24, 2026.
Earlier: Lilly dismisses its retatrutide suit against Aesthetic Envy
Eli Lilly filed a notice of voluntary dismissal, with prejudice, of its lawsuit against Aesthetic Envy Cosmetic Centers LLC in the U.S. District Court for the Eastern District of California (No. 2:26-cv-02764). It was one of the six retatrutide suits Lilly announced on August 12, 2026. The notice cites Federal Rule of Civil Procedure 41(a)(1)(A)(i) and states that the defendant had not served an answer or a motion for summary judgment.
A dismissal of this kind is not a court ruling on Lilly's allegations. No court found that Aesthetic Envy did or did not sell retatrutide or violate any law. “With prejudice” means Lilly cannot refile the same claims against that defendant. The notice gives no reason for the dismissal and does not mention a settlement; PeptideSciences101 has not seen any public settlement terms.
Separately, the court docket in Lilly's suit against Astra LLC (Western District of Texas, No. 5:26-cv-05147) lists a notice of voluntary dismissal filed September 2, 2026, two days after Lilly filed an amended complaint. The notice itself was not publicly available when we checked, so we have not confirmed its scope or whether it was filed with or without prejudice.
Court records: Notice of Voluntary Dismissal With Prejudice, Eli Lilly and Company v. Aesthetic Envy Cosmetic Centers LLC, E.D. Cal., filed September 11, 2026; Docket, Eli Lilly and Company v. Astra LLC, W.D. Tex..
FDA posted warning letters dated August 24, 2026 to online peptide sellers. One, to TXP Innovations LLC dba Tex Peptides, lists a product the firm marketed as retatrutide (“GLP-3 RT”) alongside semaglutide, tirzepatide, and bacteriostatic water. FDA stated that despite “research use only” labeling, the firm's website showed the products were intended as drugs for human use.
A warning letter states FDA's position; it is not a court judgment. TXP Innovations LLC is a different legal entity name from Texas Peptides Inc., a defendant in one of Lilly's suits; we have not determined whether the two businesses are related.
Primary source: FDA warning letter — TXP Innovations LLC dba Tex Peptides, August 24, 2026.
Earlier: Brazil orders seizure of United Labz products
Brazil's health regulator, Anvisa, ordered the seizure of all products sold under the United Labz brand and prohibited their manufacture, storage, distribution, sale, importation, advertising, and use in Brazil. Anvisa said the products were made by an unknown manufacturer and lacked required registration, notification, or sanitary authorization.
This is an official regulatory action, not merely a private-company allegation. It does not, by itself, establish that a particular product contained or did not contain the ingredient shown on its label, nor is it a criminal conviction. It establishes that Anvisa ordered the products removed from lawful commerce in Brazil on the regulatory grounds stated by the agency.
The action matters to retatrutide coverage because Anvisa has also separately warned that retatrutide remains investigational and is not approved for sale. Earlier in 2026, the agency ordered seizure of products labeled “Retatrutide 40 mg” and later reported finding retatrutide during enforcement operations involving irregular weight-loss products.
Primary sources: Anvisa — United Labz seizure order announcement; Anvisa — retatrutide approval-status warning; Anvisa — February 2026 seizure action.
Can a company “own” a peptide?
Not in the simplistic sense that often appears online. A company generally cannot claim ownership of a naturally occurring hormone merely because it discovered or isolated it. U.S. patent law has a product-of-nature doctrine, and patent eligibility is only the first hurdle: an invention must also satisfy requirements such as novelty, non-obviousness, and adequate disclosure.
But medicinal chemists can start with a natural peptide and engineer a molecule that does not occur in nature — for example by changing amino acids, introducing noncanonical residues, adding linkers or fatty-acid chains, or altering stability and receptor activity. A sufficiently novel and non-obvious engineered composition can be patentable.
The useful question is therefore not “Is this peptide natural?” It is “What exactly do the patent claims cover?”
What a peptide patent actually covers
A patent is principally a right to exclude others from practicing the claimed invention for the patent term. Depending on the claims, peptide intellectual property can cover a specific molecular sequence, a family of analogs, substitutions at defined positions, conjugates, formulations, manufacturing methods, or methods of use.
The description section of a patent may discuss hundreds of compounds. The legal boundary is driven primarily by the claims. Two patents that both mention GLP-1 can therefore have dramatically different scope.
Primary legal sources: 35 U.S.C. §101, §102, §103, and §271.
Case file: retatrutide
October 8, 2026: Five additional Lilly retatrutide lawsuits reported
Five additional federal civil actions attributed to Eli Lilly were reported as filed on October 8, 2026. The named defendants and reported docket numbers are American Peptides LLC (W.D. La., 5:26-cv-04146), Cenexa Labs LLC (S.D. Tex., 4:26-cv-08806), William Ian Brown, doing business as LiveWell Peptides (N.D. Tex., 3:26-cv-03514), MedShape Weight Loss Clinic LLC (D. Ariz., 2:26-cv-07361), and Southlake Mhya PLLC, reportedly doing business as Medrein Health & Aesthetics (N.D. Tex., 4:26-cv-01294).
Procedural status and sourcing: These are reported lawsuit filings, not court findings. The complete complaints and subsequent docket activity have not been independently reviewed for this update. Lilly's allegations concerning the marketing or sale of products represented as retatrutide must not be treated as proven violations, and the filings alone do not establish the chemical identity of any products. No judgment, injunction, or settlement in these five actions is established by this entry. The reported five cases are separate from the six actions Lilly announced in August 2026; their procedural statuses must be tracked individually, including any dismissals.
Why it matters: The reported expansion reaches peptide sellers and clinic or aesthetics businesses. It highlights the distinction between a “research use only” label and evidence of intended human-drug use. Retatrutide remains investigational; a civil complaint does not change its FDA approval or compounding status.
Retatrutide is an especially useful example because the internet often collapses two different ideas into one: “the body already has these hormones” and “therefore the drug cannot be patented.”
Human GIP, GLP-1, and glucagon are naturally occurring signaling molecules. Retatrutide is not simply one of those hormones placed in a vial. It is an engineered peptide analog designed to activate the GIP, GLP-1, and glucagon receptors, with deliberate structural modifications that affect its pharmacology and pharmacokinetics.
Lilly's U.S. Patent 11,542,313, titled Incretin Analogs and Uses Thereof, claims defined engineered incretin analogs and related subject matter. That is materially different from claiming ownership of GIP, GLP-1, glucagon, amino acids, or the receptors in the human body.
Patent source: U.S. Patent 11,542,313.
October 2, 2026: Legendary Peptides files motion to dismiss
In Eli Lilly and Company v. Legendary Peptides, LLC, E.D. Tex., No. 1:26-cv-00347, the defendant filed a motion to dismiss on October 2, 2026 (docket entry 12), invoking Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6). This is a defense filing, not a court ruling. No decision on the motion has been verified.
Reporting on the motion describes challenges to Lilly's asserted injury from sales of a drug that Lilly has not yet commercially marketed, as well as challenges concerning alleged consumer harm. Those are reported defense arguments, not established facts. The full motion has not been independently reviewed, so this tracker does not attribute more specific language to the filing. The motion does not change FDA's position on investigational retatrutide or authorize its sale for human use.
Court reference: E.D. Tex., No. 1:26-cv-00347, docket entry 12, October 2, 2026. Full motion text pending independent verification.
Lilly's 2026 retatrutide lawsuits
On August 12, 2026, Eli Lilly announced six federal lawsuits against U.S. businesses it accused of selling products represented as retatrutide. Those allegations are not court findings merely because a complaint was filed.
Importantly, the complaint reviewed by PeptideSciences101 in the Legendary Peptides matter pleads state unfair-competition and consumer-protection theories surrounding alleged sale of an unapproved drug; its enumerated causes of action do not include a patent-infringement count. That distinction is central to this section: patent enforcement and drug-law enforcement are different legal systems.
Sources: Lilly announcement, August 12, 2026 (company statement; allegations should not be treated as findings).
Case status as of September 26, 2026
On the CourtListener copies of the dockets we reviewed, which may lag the official court record, no court has ruled on the merits, issued an injunction, or entered a judgment in any of the six cases.
- Aesthetic Envy Cosmetic Centers LLC (E.D. Cal., No. 2:26-cv-02764): Lilly voluntarily dismissed the case with prejudice on September 11, 2026. No findings were made.
- Astra LLC (W.D. Tex., No. 5:26-cv-05147): Lilly filed an amended complaint on August 31, 2026; the docket lists a notice of voluntary dismissal filed September 2, 2026. Its terms are unverified.
- Legendary Peptides, LLC (E.D. Tex., No. 1:26-cv-00347): filed a motion to dismiss on October 2, 2026 (entry 12). The motion is pending; no ruling has been verified.
- Striker Pharmacy, LLC (S.D. Tex., No. 4:26-cv-06563), Lone Star Peptide Co. LLC (S.D. Tex., No. 4:26-cv-06562), and Texas Peptides Inc. (W.D. Tex., No. 5:26-cv-05146): pending, with only procedural filings so far.
Court records: Aesthetic Envy notice of dismissal; Legendary Peptides order, September 10, 2026; Astra docket.
Patent law is not FDA law
A molecule can be patented and still be unapproved. A patent can expire while FDA restrictions remain. FDA approval can exist while patent rights still block a competitor from marketing a copy.
For retatrutide, FDA currently treats the molecule as investigational, not an FDA-approved drug. That regulatory status is independent of whether Lilly holds enforceable patent claims.
For a broader status comparison, see FDA-approved vs research-only peptides.
What “research use only” does — and does not — do
“Research use only” is not a magic phrase that overrides how a product is actually marketed. FDA evaluates evidence of intended use. Human-effect claims, weight-loss claims, administration or reconstitution context, and other surrounding conduct can matter even when a product page or vial also says “not for human consumption.”
That does not mean legitimate laboratory research reagents cannot be sold. It means the regulatory analysis is based on the full context, not solely on the disclaimer.
Related FDA reference: FDA — concerns with unapproved GLP-1 drugs used for weight loss.
503A / 503B compounding: a separate question again
Pharmacy compounding operates under separate provisions of federal law, principally sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Whether a bulk substance may be used in compounding depends on criteria that are distinct from patent ownership.
FDA has stated that retatrutide cannot currently be used in compounding under federal law because it is not a component of an FDA-approved drug and does not currently satisfy the applicable bulk substance pathways. That status can change only through the regulatory process — not because a seller calls a product a “research peptide.”
How to read a peptide patent without being a patent attorney
- Start with the independent claims. They define the broadest claimed inventions.
- Then read the dependent claims. These narrow the invention with additional structural or functional limitations.
- Find the sequence identifiers. A claim may point to a SEQ ID while the specification provides the actual sequence and modification map.
- Check the patent family. Continuations and related applications can produce multiple patents with different claim scope around the same development program.
- Check status and jurisdiction. A U.S. patent is not a worldwide monopoly, and an application is not the same as an issued, enforceable patent.
What PeptideSciences101 is watching
This section will be updated when a development materially changes the legal or regulatory picture: court rulings, injunctions, settlements, patent decisions, FDA warning letters or enforcement, 503A/503B changes, and significant actions by pharmaceutical companies or regulators in other major jurisdictions.
- Lilly v. Kennedy, No. 26-1301 (added September 30, 2026): supplemental jurisdiction memoranda due October 8, followed by any Seventh Circuit jurisdictional disposition or merits decision; also watch FDA's action on the analogous-product remand.
- Lilly's remaining retatrutide suits (updated September 26, 2026): whether Legendary Peptides files a motion to dismiss, and any ruling, injunction, settlement, or judgment in the Legendary Peptides, Striker Pharmacy, Lone Star Peptide, and Texas Peptides cases.
- Astra LLC dismissal (added September 26, 2026): the scope and terms of the notice of voluntary dismissal listed on the docket on September 2, 2026.
About this series: Peptides, Patents & the Law examines intellectual-property and regulatory issues for educational reference. Patent coverage can depend on claim construction, validity, jurisdiction, and facts not visible from a patent's title alone. Regulatory status can change. Nothing on this page constitutes legal advice or medical advice.